, The Company’s strategies such as increasing more specialty cilinics, medical instruments and expanding into new market so as to drive a sustainable growth Cost of Hospital Operations The costs of

30.69 1.90 6.21 Total revenue 1,151,091 1,374,128 (223,037) (16.23) 2,970,715 2,646,863 323,852 12.24 Total Cost & Expenses 1,013,853 1,243,461 (229,608) (18.47) 2,699,583 2,466,406 233,177 9.45 Selling

record high depreciation cost in full which did not correspond to such low utilization of production and machinery. The Company engaged independent engineering expert to inspect and appraise the assets and

other expenses were 2,035 million baht, increased by 112 million baht or 6% y-y due to increase of advertising expense 55% y-y. However, the Company still maintained effective operating cost control with

88 million baht or 5% y-y and 3% q-q. However, the Company still maintained effective operating cost control with cost to income ratio at 35% of total revenues. Considering the Company’s separate

improved following on-going cost optimization and FY17 guidance maintained. AIS reported 3Q17 EBITDA of Bt17,589mn, +15% YoY and +2.8% QoQ, mainly due to revenue growth and controlled SG&A. YTD, AIS spent

high profit margin and also from effective marketing policy. (2) Analysis of Operating Results and Profitability (2.1) Revenues from Sales and Services Description Year 2018 Year 2017 Increase

; higher depreciation; higher excise tax and sugar tax following the Excise Act, B.E. 2560 which was effective since 16 September 2017; cost from trial runs and start-up of a new production line, driving

construction under a concession arrangement 131.3 398.1 215.0 126.1 (88.9) (41.3%) 104.6 870.5 765.9 732.2% Cost of sales and services (788.7) (796.3) (822.9) (788.4) (34.5) (4.2%) (3,324.7) (3,196.3) (128.4

shareholder in the amount of USD 9.51 million. The Company additionally received opportunity cost in the amount of Baht 10 million. Such sale of shares is a termination of joint investment for the development